2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2212

Identification of a Novel Chemokine-Dependent Molecular Mechanism Underlying Rheumatoid Arthritis-Associated Autoantibody-Mediated Bone Destruction
Abstract Number: 1258

Identification of a Spectrum of Therapeutic Targets of a New Treatment for Osteoarthritis Composed By Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract
Abstract Number: 1750

Identification of Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) That Causes Systemic Lupus Erythematosus (SLE) As DOCK8+ CD4 T Cell: Proof of Concept of Self-Organized Criticality Theory
Abstract Number: 775

Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus
Abstract Number: 1095

Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis
Abstract Number: 802

Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus
Abstract Number: 15L

Identification of Four-and-a-Half-LIM Domain 1 (FHL1) As a New Autoantibody Target in Idiopathic Inflammatory Myopathies
Abstract Number: 1616

Identification of Genes Regulating TRAIL-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-like Synoviocytes (RA FLS)
Abstract Number: 1953

Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis
Abstract Number: 2094

Identification of Gout Flare Using an Administrative Claims Based Algorithm
Abstract Number: 1862

Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities
Abstract Number: 2278

Identification of Long-Term Physical Activity Trajectories in Individuals with Chronic Widespread Pain Who Received Exercise Treatment As Part of a Randomized Controlled Trial
Abstract Number: 788

Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Abstract Number: 1134

Identification of Novel Micro-RNAs in IL-1β-Stimulated OA Chondrocytes By Next-Generation Sequencing
Abstract Number: 3227

Identification of Novel Protein-Coding Genetic Variants Associated with Takayasu Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].